Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 0.47
WAG's Cash to Debt is ranked higher than
62% of the 501 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 0.70 vs. WAG: 0.47 )
WAG' s 10-Year Cash to Debt Range
Min: 0.03   Max: No Debt
Current: 0.47

Equity to Asset 0.57
WAG's Equity to Asset is ranked higher than
86% of the 501 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 0.44 vs. WAG: 0.57 )
WAG' s 10-Year Equity to Asset Range
Min: 0.52   Max: 0.64
Current: 0.57

0.52
0.64
F-Score: 6
Z-Score: 5.99
M-Score: -2.27
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 5.46
WAG's Operating margin (%) is ranked higher than
85% of the 477 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 3.80 vs. WAG: 5.46 )
WAG' s 10-Year Operating margin (%) Range
Min: 4.84   Max: 6.05
Current: 5.46

4.84
6.05
Net-margin (%) 3.39
WAG's Net-margin (%) is ranked higher than
83% of the 477 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 2.36 vs. WAG: 3.39 )
WAG' s 10-Year Net-margin (%) Range
Min: 2.97   Max: 3.8
Current: 3.39

2.97
3.8
ROE (%) 12.59
WAG's ROE (%) is ranked higher than
81% of the 469 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 10.66 vs. WAG: 12.59 )
WAG' s 10-Year ROE (%) Range
Min: 11.66   Max: 18.39
Current: 12.59

11.66
18.39
ROA (%) 6.91
WAG's ROA (%) is ranked higher than
86% of the 477 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 4.41 vs. WAG: 6.91 )
WAG' s 10-Year ROA (%) Range
Min: 6.36   Max: 10.94
Current: 6.91

6.36
10.94
ROC (Joel Greenblatt) (%) 28.99
WAG's ROC (Joel Greenblatt) (%) is ranked higher than
85% of the 476 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 20.19 vs. WAG: 28.99 )
WAG' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 22.73   Max: 30.69
Current: 28.99

22.73
30.69
Revenue Growth (%) 3.50
WAG's Revenue Growth (%) is ranked higher than
71% of the 439 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 4.90 vs. WAG: 3.50 )
WAG' s 10-Year Revenue Growth (%) Range
Min: 3.5   Max: 16.5
Current: 3.5

3.5
16.5
EBITDA Growth (%) 6.40
WAG's EBITDA Growth (%) is ranked higher than
78% of the 399 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 5.00 vs. WAG: 6.40 )
WAG' s 10-Year EBITDA Growth (%) Range
Min: 6.1   Max: 17.9
Current: 6.4

6.1
17.9
EPS Growth (%) 6.50
WAG's EPS Growth (%) is ranked higher than
77% of the 378 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 6.30 vs. WAG: 6.50 )
WAG' s 10-Year EPS Growth (%) Range
Min: 1.5   Max: 20
Current: 6.5

1.5
20
» WAG's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2013

WAG Guru Trades in Q3 2013

Jim Simons 1,451,800 sh (New)
Louis Moore Bacon 10,000 sh (New)
George Soros 500,000 sh (New)
Paul Tudor Jones 100,000 sh (New)
John Hussman 296,500 sh (+46.42%)
Jeremy Grantham 3,640,147 sh (+28.17%)
Ken Fisher 5,755 sh (+18.44%)
Steven Cohen 73,290 sh (+15%)
Manning & Napier Advisors, Inc 97,616 sh (+5.34%)
Tom Gayner 2,149,200 sh (+0.07%)
Vanguard Health Care Fund 12,465,900 sh (unchged)
Caxton Associates 800,000 sh (unchged)
Steven Romick 2,175,000 sh (unchged)
Joel Greenblatt Sold Out
John Buckingham 152,337 sh (-0.35%)
First Pacific Advisors 2,288,500 sh (-0.38%)
Pioneer Investments 2,324,514 sh (-1.22%)
Bill Frels 16,788 sh (-1.32%)
Larry Robbins 7,442,926 sh (-1.75%)
RS Investment Management 49,300 sh (-2.18%)
Dodge & Cox 6,069 sh (-6.18%)
Mario Gabelli 191,450 sh (-7.85%)
James Barrow 7,571,176 sh (-12.45%)
John Rogers 104,630 sh (-36.38%)
Chuck Royce 3,000 sh (-94.2%)
» More
Q4 2013

WAG Guru Trades in Q4 2013

John Keeley 3,682 sh (New)
Andreas Halvorsen 11,604,944 sh (New)
Steven Cohen 335,584 sh (+357.89%)
RS Investment Management 52,100 sh (+5.68%)
George Soros 515,700 sh (+3.14%)
First Pacific Advisors 2,295,200 sh (+0.29%)
Pioneer Investments 2,325,918 sh (+0.06%)
Steven Romick 2,175,000 sh (unchged)
Dodge & Cox 6,069 sh (unchged)
Eric Mindich 1,000,000 sh (unchged)
Chuck Royce Sold Out
Louis Moore Bacon Sold Out
John Rogers Sold Out
Tom Gayner 2,147,450 sh (-0.08%)
Ken Fisher 5,737 sh (-0.31%)
John Buckingham 150,884 sh (-0.95%)
Mario Gabelli 188,750 sh (-1.41%)
Jeremy Grantham 3,555,906 sh (-2.31%)
Jim Simons 1,387,600 sh (-4.42%)
James Barrow 6,972,657 sh (-7.91%)
Vanguard Health Care Fund 10,913,200 sh (-12.46%)
Bill Frels 14,013 sh (-16.53%)
Larry Robbins 5,951,526 sh (-20.04%)
Manning & Napier Advisors, Inc 70,004 sh (-28.29%)
John Hussman 150,000 sh (-49.41%)
Paul Tudor Jones 14,008 sh (-85.99%)
» More
Q1 2014

WAG Guru Trades in Q1 2014

Stanley Druckenmiller 1,240,000 sh (New)
Louis Moore Bacon 244,750 sh (New)
John Griffin 3,435,000 sh (New)
Andreas Halvorsen 24,105,841 sh (+107.72%)
George Soros 850,000 sh (+64.82%)
Paul Tudor Jones 19,946 sh (+42.39%)
RS Investment Management 56,200 sh (+7.87%)
First Pacific Advisors 2,304,500 sh (+0.41%)
Steven Romick 2,175,000 sh (unchged)
Eric Mindich 1,000,000 sh (unchged)
John Keeley 3,682 sh (unchged)
Dodge & Cox 6,069 sh (unchged)
Larry Robbins 500,000 sh (unchged)
John Hussman Sold Out
John Buckingham Sold Out
Jim Simons Sold Out
Pioneer Investments 2,316,700 sh (-0.4%)
Tom Gayner 2,135,000 sh (-0.58%)
Manning & Napier Advisors, Inc 69,126 sh (-1.25%)
Vanguard Health Care Fund 10,073,000 sh (-7.7%)
Mario Gabelli 172,950 sh (-8.37%)
Bill Frels 12,663 sh (-9.63%)
Larry Robbins 5,190,926 sh (-12.78%)
Ken Fisher 4,263 sh (-25.69%)
Jeremy Grantham 662,105 sh (-81.38%)
James Barrow 960,997 sh (-86.22%)
Steven Cohen 24,535 sh (-92.69%)
» More
Q2 2014

WAG Guru Trades in Q2 2014

Ken Fisher 4,754 sh (+11.52%)
Steven Romick 2,175,000 sh (unchged)
Manning & Napier Advisors, Inc 14,515 sh (-79%)
» More
» Details

Insider Trades

Latest Guru Trades with WAG

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
John Griffin 2014-03-31 New Buy2.5%$55.57 - $69.09 $ 73.2917%3435000
John Hussman 2014-03-31 Sold Out 0.61%$55.57 - $69.09 $ 73.2917%0
James Barrow 2014-03-31 Reduce -86.22%0.5%$55.57 - $69.09 $ 73.2917%960997
George Soros 2014-03-31 Add 64.82%0.22%$55.57 - $69.09 $ 73.2917%850000
Vanguard Health Care Fund 2014-03-31 Reduce -7.7%0.15%$55.57 - $69.09 $ 73.2917%10073000
John Hussman 2013-12-31 Reduce -49.41%0.43%$54.86 - $60.59 $ 73.2926%150000
Vanguard Health Care Fund 2013-12-31 Reduce -12.46%0.29%$54.86 - $60.59 $ 73.2926%10913200
John Keeley 2013-12-31 New Buy$54.86 - $60.59 $ 73.2926%3682
George Soros 2013-09-30 New Buy0.29%$44.12 - $56.23 $ 73.2946%500000
John Hussman 2013-09-30 Add 46.42%0.28%$44.12 - $56.23 $ 73.2946%296500
Joel Greenblatt 2013-09-30 Sold Out 0.02%$44.12 - $56.23 $ 73.2946%0
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Top Ranked Articles about Walgreen Co

NEW SITE FEATURE: 10-Year Median Scans
GuruFocus has always delievered the most vast offering of equity research tools available on the market. Last year we introduced the All-In-One Guru Screener. It has been met with immensely positive feedback and has quickly become the go-to scanner for sophisticated investors. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 25.00
WAG's P/E(ttm) is ranked higher than
68% of the 517 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 20.40 vs. WAG: 25.00 )
WAG' s 10-Year P/E(ttm) Range
Min: 10.2   Max: 32.02
Current: 25

10.2
32.02
P/B 3.27
WAG's P/B is ranked higher than
58% of the 517 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 2.09 vs. WAG: 3.27 )
WAG' s 10-Year P/B Range
Min: 1.6   Max: 5.58
Current: 3.27

1.6
5.58
P/S 0.94
WAG's P/S is ranked higher than
57% of the 517 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 0.47 vs. WAG: 0.94 )
WAG' s 10-Year P/S Range
Min: 0.36   Max: 1.2
Current: 0.94

0.36
1.2
PFCF 28.52
WAG's PFCF is ranked higher than
78% of the 517 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 48.35 vs. WAG: 28.52 )
WAG' s 10-Year PFCF Range
Min: 9.86   Max: 368.77
Current: 28.52

9.86
368.77
EV-to-EBIT 17.06
WAG's EV-to-EBIT is ranked higher than
69% of the 517 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 15.68 vs. WAG: 17.06 )
WAG' s 10-Year EV-to-EBIT Range
Min: 6.3   Max: 19.9
Current: 17.06

6.3
19.9
PEG 3.72
WAG's PEG is ranked higher than
78% of the 517 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 7.78 vs. WAG: 3.72 )
WAG' s 10-Year PEG Range
Min: 0.69   Max: 4.13
Current: 3.72

0.69
4.13
Shiller P/E 28.05
WAG's Shiller P/E is ranked higher than
84% of the 517 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 56.34 vs. WAG: 28.05 )
WAG' s 10-Year Shiller P/E Range
Min: 12.17   Max: 42.41
Current: 28.05

12.17
42.41
Current Ratio 1.42
WAG's Current Ratio is ranked higher than
78% of the 504 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 1.21 vs. WAG: 1.42 )
WAG' s 10-Year Current Ratio Range
Min: 1.23   Max: 1.93
Current: 1.42

1.23
1.93
Quick Ratio 0.65
WAG's Quick Ratio is ranked higher than
69% of the 504 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 0.68 vs. WAG: 0.65 )
WAG' s 10-Year Quick Ratio Range
Min: 0.27   Max: 0.82
Current: 0.65

0.27
0.82

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 1.72
WAG's Dividend Yield is ranked higher than
51% of the 430 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 1.79 vs. WAG: 1.72 )
WAG' s 10-Year Dividend Yield Range
Min: 0.44   Max: 3.11
Current: 1.72

0.44
3.11
Dividend Payout 0.43
WAG's Dividend Payout is ranked higher than
83% of the 517 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 1.56 vs. WAG: 0.43 )
WAG' s 10-Year Dividend Payout Range
Min: 0.1   Max: 0.7
Current: 0.43

0.1
0.7
Dividend growth (3y) 24.70
WAG's Dividend growth (3y) is ranked higher than
95% of the 339 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 4.20 vs. WAG: 24.70 )
WAG' s 10-Year Dividend growth (3y) Range
Min: 3.7   Max: 26
Current: 24.7

3.7
26
Yield on cost (5-Year) 5.19
WAG's Yield on cost (5-Year) is ranked higher than
84% of the 429 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 1.93 vs. WAG: 5.19 )
WAG' s 10-Year Yield on cost (5-Year) Range
Min: 1.34   Max: 9.49
Current: 5.19

1.34
9.49
Share Buyback Rate 1.10
WAG's Share Buyback Rate is ranked higher than
87% of the 340 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: -0.20 vs. WAG: 1.10 )
WAG' s 10-Year Share Buyback Rate Range
Min: 3.9   Max: -0.9
Current: 1.1

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 3.92
WAG's Price/Tangible Book is ranked higher than
63% of the 517 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 3.44 vs. WAG: 3.92 )
WAG' s 10-Year Price/Tangible Book Range
Min: 1.94   Max: 10.32
Current: 3.92

1.94
10.32
Price/DCF (Projected) 1.62
WAG's Price/DCF (Projected) is ranked higher than
86% of the 517 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 8.31 vs. WAG: 1.62 )
WAG' s 10-Year Price/DCF (Projected) Range
Min: 0.73   Max: 18.65
Current: 1.62

0.73
18.65
Price/Median PS Value 1.44
WAG's Price/Median PS Value is ranked higher than
57% of the 517 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 1.11 vs. WAG: 1.44 )
WAG' s 10-Year Price/Median PS Value Range
Min: 0.57   Max: 3.19
Current: 1.44

0.57
3.19
Price/Peter Lynch Fair Value 4.04
WAG's Price/Peter Lynch Fair Value is ranked higher than
85% of the 517 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 9999.00 vs. WAG: 4.04 )
WAG' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.8   Max: 3.96
Current: 4.04

0.8
3.96
Price/Graham Number 2.05
WAG's Price/Graham Number is ranked higher than
69% of the 517 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 2.15 vs. WAG: 2.05 )
WAG' s 10-Year Price/Graham Number Range
Min: 0.96   Max: 5.06
Current: 2.05

0.96
5.06
Earnings Yield (Greenblatt) 5.90
WAG's Earnings Yield (Greenblatt) is ranked higher than
64% of the 486 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 6.80 vs. WAG: 5.90 )
WAG' s 10-Year Earnings Yield (Greenblatt) Range
Min: 5   Max: 15.9
Current: 5.9

5
15.9
Forward Rate of Return (Yacktman) 9.38
WAG's Forward Rate of Return (Yacktman) is ranked higher than
74% of the 349 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 10.61 vs. WAG: 9.38 )
WAG' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 9.9   Max: 17.8
Current: 9.38

9.9
17.8

Business Description

Industry: Retail - Defensive » Pharmaceutical Retailers
Compare:SHDMF, APNHF, GNC, JCOUF, PMC » details
Traded in other countries:WGN.Germany
Walgreen Company was incorporated in the state of Illinois in 1909 as a successor to a business founded in 1901. Its corporate strategy is to provide convenient access to healthcare services and consumer goods in America through its 7,930 community based drugstores, as well as through its specialty pharmacy, home infusion, worksite health center and retail clinic businesses. The Company's drugstores are engaged in the retail sale of prescription and non-prescription drugs and general merchandise. General merchandise includes, among other things, household items, personal care, convenience foods, beauty care, photofinishing, candy, and seasonal items. Walgreens offers customers the choice to have prescriptions filled at the drugstore counter, as well as through the mail, by telephone and via the Internet. Inventories are purchased from numerous domestic and foreign suppliers. The business is seasonal in nature, with Christmas generating a higher proportion of front-end sales and earnings than other periods. Both prescription and non-prescription drug sales are affected by the timing and severity of the cold/flu season. The Company generally finances its inventory and expansion needs with internally generated funds. It sells to numerous customers including managed care organizations. Walgreens competes with different retailers, including chain and independent drugstores, mail order prescription providers, grocery stores, convenient stores, mass merchants and dollar stores. Its retail drugstore, pharmacy benefit and health services businesses are subject to numerous federal, state and local regulations.
» More Articles for WAG

Headlines

Articles On GuruFocus.com
Realty Income: Another BORING and Solid Quarter for the Monthly Dividend Company Jul 24 2014 
Looking beyond Walgreen’s Quarter Jul 21 2014 
Here's Why Rite Aid and Walgreens Are Still Solid Picks May 29 2014 
3 Stocks To Strike A Balance Between Dividend And Growth May 27 2014 
NEW SITE FEATURE: 10-Year Median Scans May 21 2014 
Rite Aid Corporation May Be a Buy: More Upside Expected May 20 2014 
Why I AM Buying American Realty Capital Properties Apr 28 2014 
Weekly Insider Sells Highlight: ATHN, GILD, JPM, WAG Apr 20 2014 
Walgreen Co. (WAG) Dividend Stock Analysis Mar 28 2014 
How Peter Lynch Earned 29% a Year for 13 years Mar 14 2014 


More From Other Websites
Digital Coupon Campaign: Getting To Know Coupons.com Via Walgreens, Mir Aamir Jul 27 2014
Walgreens eyes loophole end run around taxes Jul 26 2014
Mark Cuban: Companies moving overseas will raise everyone’s taxes Jul 25 2014
[video] Obama Calls Congress to Take Action to Stop Inversions Jul 25 2014
A Note To Congresswoman Schakowsky, A Walgreens Tax Inversion Would Not Work Quite As You Think It... Jul 25 2014
Obama rails against corporate maneuver to evade U.S. taxes Jul 24 2014
Obama steps up criticism of tax inversions Jul 24 2014
Walgreens "Way to Well" Health Tour Reaches Millionth Community Member With Free Health Tests Jul 24 2014
WALGREEN CO Files SEC form 8-K, Change in Directors or Principal Officers Jul 24 2014
Walgreens President of Pharmacy, Health and Wellness Kermit Crawford Announces Retirement from... Jul 24 2014
[$$] Walgreen Pharmacy Chief to Retire Jul 24 2014
Walgreens President of Pharmacy, Health and Wellness Kermit Crawford Announces Retirement from... Jul 24 2014
Yesterday's Unusual Options Activity: $SPLS, $WAG, $RIO, $PBR, $TLM, $AAPL Jul 24 2014
Will AmerisourceBergen (ABC) Beat This Earnings Season? Jul 23 2014
Cardtronics to Acquire Welch ATM, Boost National Presence Jul 23 2014
Durbin Harshly Criticizes Walgreen for Tax Inversion Plans Jul 23 2014
[video] Don't Expect Tax Inversion Fever to Break Anytime Soon Jul 22 2014
Top U.S. lawmaker wants corporate tax loophole 'plugged now' Jul 22 2014
Top U.S. lawmaker wants corporate tax loophole 'plugged now' Jul 22 2014
Top U.S. lawmaker wants corporate tax loophole 'plugged now' Jul 22 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Email Hide